Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

NCT05114746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

RADIATION: 177Lu-PSMA-617
RADIATION: 68Ga-PSMA-11
OTHER: Best supportive/best standard of care

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]